CACNA1D
CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
Overview
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes clinical 0.62, literature 0.66, genetic association 0.00, somatic mutation 0.83, animal model 0.39). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Hepatocellular Carcinoma, Sarcoma, NOS, Stomach Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
- 1 · What it is
CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
- 2 · What goes wrong in cancer
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death.
- 3 · How drugs use it
No product in this corpus aims at CACNA1D yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:1391 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q01668 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000157388 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.52, gastric cancer 0.53, prostate cancer 0.52, melanoma 0.52, skin cancer 0.57, breast cancer 0.62 (GraphQL API, CC0)); IntOGen CACNA1D (driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, and by benzothiazepines. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Location: Membrane (UniProt). Locus 3p21.1 (HGNC).
- Breast cancer: Open Targets association 0.62 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.53 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STAD)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Sarcomas: IntOGen driver in 1 cohort (SARCNOS)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.62; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CACNA1D" OR ABSTRACT:"CACNA1D" OR TITLE:"calcium voltage-gated channel subunit alpha1 D" OR ABSTRACT:"calcium voltage-gated channel subunit alpha1 D" OR TITLE:"Voltage-dependent L-type calcium channel subunit alpha-1D" OR ABSTRACT:"Voltage-dependent L-type calcium channel subunit alpha-1D" OR TITLE:"Cav1.3" OR ABSTRACT:"Cav1.3" OR TITLE:"CACH3" OR ABSTRACT:"CACH3" OR TITLE:"CACN4" OR ABSTRACT:"CACN4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CACNA1D, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetUSP6
Shares Lung cancer (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Hepatocellular carcinoma.
- TargetRECQL4
Shares Lung cancer (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types).
- TargetARHGEF12
Shares Lung cancer (all types), Skin cancer (all types), Renal cell carcinoma, Breast cancer (all types).
- TargetPTPRC
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetAFF4
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetFGFR4
Shares Lung cancer (all types), Sarcomas (soft tissue, bone, GIST), Hepatocellular carcinoma, Breast cancer (all types).
- TargetCLTCL1
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.